Selecta Biosciences, Inc. (SELB) Stock: Why It’s Headed Down

0
Intuit INTU Stock News

Selecta Biosciences, Inc. (SELB) is falling in the market in today’s trading session. The company, one that is focused in the biotechnology industry, is currently priced at $1.78 after tumbling -7.29% so far today. In terms of biotech companies, there are a number of factors that have the potential to generate movement in the market. News is one of the most common reasons for movement. Here are the most recent headlines surrounding SELB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 08:00AM Selecta Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Aug-07-19 07:35AM Triangle drugmaker’s new partnership could lead to big gains for gene therapy
07:00AM Selecta Biosciences Combines ImmTOR Platform with AskBios Industry-Leading Gene Therapy Platform in Strategic Partnership
Aug-01-19 08:00AM Selecta Biosciences Announces Date of Second Quarter 2019 Financial Results Conference Call
Jul-31-19 08:00AM Selecta Biosciences to Present at Canaccord Genuitys 39th Annual Growth Conference on August 7, 2019

However, when making an investing decision, prospective investors should focus on much more than news, this is especially the case in the speculative biotechnology space. Here’s what’s going on with Selecta Biosciences, Inc..

What We’ve Seen From SELB

While a move toward the top in a single session, like what we’re seeing from Selecta Biosciences, Inc. may make some investors fearful, that by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s generally smart to look at trends experienced by the stock further out than a single trading session. When it comes to SELB, below are the trends that we’ve seen:

  • Past Seven Days – Throughout the past 7 days, SELB has seen a change in value in the amount of -14.42%.
  • Monthly – The monthly returns from Selecta Biosciences, Inc. works out to 4.09%.
  • Past Quarter – Over the last three months, the company has produced a ROI that comes to -25.83%
  • Past 6 Months – Throughout the past 6 months, we have seen a change that equates to 1.14% from the stock.
  • This Year So Far – Since the close of last year SELB has generated a return on investment of -33.08%.
  • Full Year – Lastly, over the last year, investors have seen performance of -86.69% out of SELB. Throughout this period of time, the stock has traded at a high of -89.24% and a low of 26.24%.

Key Ratios

Digging into various key ratios associated with a company can provide prospective traders a look of how risky and/or rewarding a an investment option might be. Here are some of the important ratios to look at when looking at SELB.

Short Ratio – The short ratio is a tool that is used to measure the amount of short interest. As the ratio heads up, it shows that more investors believe that the stock is headed for declines. In general, biotechnology stocks can carry a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, when it comes to Selecta Biosciences, Inc., it’s short ratio comes to 5.58.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure whether or not a company can pay for its debts as they mature using quick assets or current assets. In the biotech industry, many companies are reliant on the continuation of support from investors, these ratios can seem damning. Nonetheless, several better companies in the biotechnology industry do have positive current and quick ratios. As far as SELB, the quick and current ratios total up to 1.80 and 1.80 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the current book value of assets that are owned by the company. In this case, that ratio is 0.39.

Cash To Share Value – Finally, the cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is a very important ratio to consider. In this case, the cash to share value is 1.03.

How Analysts Feel About Selecta Biosciences, Inc.

Although it’s not a smart idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their analysis in order to validate your own before making investment decisions in the biotech space. Here are the recent moves that we have seen from analysts when it comes to SELB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-27-18 Initiated Janney Buy $33
Mar-30-17 Reiterated UBS Buy $26

Big Money And Selecta Biosciences, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SELB, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors hold 57.30% of Selecta Biosciences, Inc.. However, it is important to mention that the ownership held by institutions has seen a move of 6.48% in the last 3 months.
  • Insider Holdings – as it relates to insiders, those close to the company currently hold 0.30% of the company. Insider ownership of the company has changed by 0 throughout the last quarter.

Interested In How Many Shares Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 47.07M shares of Selecta Biosciences, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SELB has a float of 36.70M.

It’s also important to look at the short percentage of the float. Think about it, if a large percentage of the float available for trading is sold short, the overall opinion in the market is that the equity is headed for a deep dive. With regard to SELB, the percentage of the float that is currently being sold short is 4.18%. Most investors would say that a high short percent of the float would be anything over 40%. In my research, I’ve seen that a short percent of the float over 26% is usually a risky play.

Financial Performance

What have ween seen from SELB in terms of financial results?Here’s what we’ve seen and what’s coming:

  • Analyst Expectations – As it stands at the moment, analysts are expecting that the company will generate earnings per diluted share of -1.28, with -0.30 to be announced in the report for the current quarter. Although this information isn’t associated with earnings, since we’re chatting about Wall Street analysts, Selecta Biosciences, Inc. is currently graded as a 1.40 considering a scale that ranges from 1 to 5 on which 1 is the worst possible Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the past half decade, Selecta Biosciences, Inc. has announced a change in sales that comes to a total of 0. Earnings per diluted share through the last half decade have seen a change of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is generally explained in today’s society, SELB has experienced a earnings change by 55.80%. SELB has also experienced movement with regard to sales volume that comes to a total of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an AI. So, based on what I am, I have the ability to learn by myself. Nonetheless, I was developed by a human and human beings play an important part in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at data? If so, leave a comment below and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here